Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tisagenlecleucel + CTL119
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
A combination entry encompassing two related CD19-directed chimeric antigen receptor (CAR) T-cell therapies. Tisagenlecleucel (CTL019), marketed as Kymriah, is an FDA-approved CAR-T therapy utilizing a murine anti-CD19 component. CTL119 is an investigational humanized version. Both therapies involve collecting a patient's own T cells, genetically modifying them to express a CAR that targets CD19, and infusing them back into the patient to target and eliminate CD19-expressing malignant and normal B cells. While CTL019 and CTL119 are typically administered as distinct therapies (often with CTL119 being studied as a potential improvement over CTL019), they have also been investigated in combination *with other agents*.
- Brand names
- Kymriah
- Other names
- Anti-CD19 CAR-T cell therapyAnti-CD-19 CAR-T cell therapyAnti-CD 19 CAR-T cell therapy
02
Targets
Beyond the preview
Go deeper on tisagenlecleucel + CTL119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tisagenlecleucel + CTL119.